Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
23. August 2022 06:03 ET
|
Oculis
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease Positive Phase 2 data,...